Metastatic melanoma patients receiving the BRAFi, vemurafenib, demonstrated increased CD8+ T-cell infiltration.83 The underlying mechanism was addressed in vivo, where BRAFi suppressed melanoma VEGF production and enhanced the infiltration of adoptively transferred T-cells in a murine melanoma model.84 This highlights the potential of combining immunotherapy with BRAFi as a means of increasing CD8+ T-cell infiltration. Here, CD8A is linked to melanoma.